TITLE:

Disseminated *Nocardia farcinica* infection in a patient with myasthenia gravis successfully treated by linezolid: a case report and literature review.

AUTHOR(S):

Tanioka, Kosuke; Nagao, Miki; Yamamoto, Masaki;
Matsumura, Yasufumi; Tabu, Hayato; Matsushima, Aki;
Uemura, Kengo; ... Takakura, Shunji; Takahashi, Ryosuke;
Ichiyama, Satoshi

CITATION:

Tanioka, Kosuke ...[et al]. Disseminated *Nocardia farcinica* infection in a patient with myasthenia gravis successfully treated by linezolid: a case report and literature review.. *Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy* 2012, 18(3): 390-394

ISSUE DATE:

2012-06

URL:

<http://hdl.handle.net/2433/160126>

RIGHT:

The final publication is available at www.springerlink.com; この論文は出版社版ではありません。引用の際には出版社版をご確認ご利用ください。 ; This is not the published version. Please cite only the published version.

1 Disseminated *Nocardia farcinica* infection in a patient with
2 myasthenia gravis successfully treated by linezolid. a case report
3 and literature review

4

5 Kosuke Tanioka¹, Miki Nagao^{2,3}, Masaki Yamamoto^{2,3}, Yasufumi
6 Matsumura^{2,3}, Hayato Tabu¹, Aki Matsushima^{2,3}, Kengo Uemura¹, Riki
7 Matsumoto¹, Yutaka Ito^{2,4}, Shunji Takakura^{2,3}, Ryosuke Takahashi¹, Satoshi
8 Ichiyama^{2,3}

9

10 ¹ Department of Neurology, Kyoto University Graduate School of Medicine

11 ² Department of Infection Control and Prevention, Kyoto University
12 Hospital,

13 ³ Department of Clinical Laboratory Medicine, Kyoto University Graduate
14 School of Medicine,

15 ⁴ Department of Respiratory Medicine, Kyoto University Graduate School of
16 Medicine

17 Shogoin Kawahara-cho 54, Sakyo-ku, Kyoto Japan

18

19 Key words : Invasive nocardiosis, Linezolid, Nocardia farcinica

20

21 Corresponding author

22 Miki Nagao, Department of Infection Control and Prevention,

23 Kyoto University Hospital

24 Shogoin Kawahara-cho 54 , Sakyo-ku, Kyoto, Japan

25 Postal code 606-8507

26 Tel & Fax +81 75 751 4967

27 Email: mnagao@kuhp.kyoto-u.ac.jp

28

29

30 **Abstract**

31 Nocardiosis is increasingly being diagnosed due to a growing population of
32 immunocompromised hosts and improvements in the detection of *Nocardia*
33 species in clinical laboratories. Historically, sulphonamides have been the
34 first-line therapy for the treatment of nocardiosis, but sulphonamides tend to
35 have high rate of drug allergy in clinical settings. In this report, we
36 described a disseminated *N. farcinica* infection occurred in a patient with
37 myasthenia gravis, who suffered from multiple drug allergies and was
38 successfully treated using linezolid. We undertook a review of literature of
39 previously reported cases of nocardiosis treated with linezolid. To date, only
40 15 cases of nocardiosis treated with linezolid have been published. All cases
41 exhibited long-term tolerance of linezolid and 14 out of 15 cases showed
42 either an improvement in or complete clearance of the infection. According
43 to the literature review, linezolid is an attractive alternative to
44 trimethoprim-sulfamethoxazole for the treatment of disseminated
45 nocardiosis, despite limited clinical evidence to support this claim.

46

Introduction

Nocardiosis is increasingly being diagnosed due to a growing population of immunocompromised hosts and improvements in the detection and identification of *Nocardia* species in clinical laboratories. However, none of the reported cases have been diagnosed concomitantly with myasthenia gravis (MG), making this the first reported case of its kind. Data regarding prognosis in nocardiosis are highly variable, with published mortality rates ranging from 14% to 40% [1-3]. In cases of disseminated infection, mortality rates may even approach 100%.

In this report, we describe a disseminated infection (with bacteraemia, multilobar pneumonia, and kidney and brain abscesses) caused by *N. farcinica* that occurred in a patient with MG. This patient suffered from multiple drug allergies and was successfully treated using linezolid. In addition reported cases of nocardiosis treated with linezolid were reviewed.

Case report

A 59-year-old woman was admitted to Kyoto University Hospital with malaise, cough and stomatitis in October 2010. She had been diagnosed

65 with myasthenia gravis (MG) one year prior to admission and had received
66 immunosuppressive treatment, including prednisolone (15mg once daily)
67 and tacrolimus. Upon admission, she appeared acutely ill and complained a
68 shortness of breath with body movement. Physical examination revealed a
69 body temperature of 36.5 °C, a respiratory rate of 24 breaths per minute,
70 blood pressure of 71/52 mm Hg, and a heart rate of 106 beats per minute.
71 Diffuse crackles were audible in both upper lungs. Laboratory tests
72 revealed hemoglobin of 8.0 mg/dL, a white blood cell count of 19,100/mm³,
73 platelet count of 465 x 10⁹/L, total protein of 4.4 g/dL, albumin of 2.4 g/dL,
74 C-reactive protein of 10.9 mg/dL, and IgG of 363 mg/dL. Chest radiographs
75 and computed tomography (CT) scanning showed extensive diffuse bilateral
76 reticulonodular infiltrates. An abdominal CT showed an abscess in the
77 right kidney, whereas a head CT did not reveal any abnormalities. Neither
78 vegetation nor valvular thickening was detected during transthoracic
79 echocardiography, which ruled out infective endocarditis. Two sets of blood
80 cultures and a sputum culture were obtained, and piperacillin-tazobactam
81 (TZP) 4.5g q8h and ciprofloxacin (CIP) 300mg q12h were started based on a
82 presumptive diagnosis of severe healthcare-associated, community-acquired

83 pneumonia and pyogenic kidney abscesses. Gram staining of the sputum
84 showed Gram-positive filaments suggestive of *Nocardia* spp. or *Actinomyces*.
85 TZP and CIP were changed to imipenem-cilastatin (IPM) 0.5g q6h and
86 trimethoprim-sulphamethoxazole (TMP) 4 tablets orally q12h on the fourth
87 day, due to a deterioration in respiratory function. On the seventh day, the
88 blood and sputum cultures collected at admission grew a “*Corynebacterium*
89 “ species, based on identification using a VITEK 2 system (bioMérieux,
90 Marcy l'Etoile, France). This culture was further identified as *N. farcinica*
91 via sequencing analysis of the 16S rRNA gene of the isolates and the
92 phenotype of the bacteria. The isolate was susceptible to cefotaxime ($\leq$
93 2.0 ug ml⁻¹), AMK ($<$ 1.0 ug ml⁻¹), CPFX (1.0 ug ml⁻¹), IPM ($\leq$ 0.5 ug ml⁻¹),
94 minocycline (MINO) (1.0 ug ml⁻¹), and resistant to gentamicin (32 ug ml⁻¹),
95 TZP (128.0 ug ml⁻¹). We changed IPM and TMP to MINO on the eighteenth
96 day due to a generalised skin rash and a facial flushing that seemed to be
97 caused by a drug allergy. Accordingly, we attempted desensitisation to TMP.
98 Cyclosporine was started on the thirty-sixth day as a treatment for MG, as
99 the physical signs of systemic illness were gradually improving.
100 On the fifty-seventh day, the patient's fever rose to 38 °C. She was free of

neurological symptoms, but multiple brain abscesses were detected by magnetic resonance imaging, and an abdominal CT showed enlargement of the abscess on the right kidney. We tried meropenem and amikacin, but infectious symptoms were not improved. Linezolid 600mg q12h was started, with subsequent improvement in the brain and right kidney abscesses. Mild thrombocytopenia developed on the ninety-seventh day (the platelet count decreased from $465 \times 10^9/L$ to $121 \times 10^9/L$), and linezolid therapy was changed to TMP. Any side effect other than mild thrombocytopenia did not occur during 38-day course of linezolid therapy. The patient was discharged on the one hundred twentieth day and was followed up at an outpatient clinic without a worsening of infectious symptoms or a severe adverse reaction to TMP.

Disucussion

We reported herein a case of disseminated *N. farcinica* infection in which the causative organism was misidentified as a *Corynebacterium* spp. and a drug allergy to the first-line therapy for nocardiosis altered antibiotic selection. *Nocardia* spp. can be cultured on most bacterial media, and thus a high

119 degree of suspicion is needed for diagnosis of nocardiosis. This includes
120 consideration of the patient's underlying illnesses and unique bacterial
121 characteristics identified via Gram and Ziehl-Neelsen staining. In the early
122 phase of growth on standard media, the organisms may resemble
123 'diphtheroid' bacilli, which commonly contaminate samples. This may lead
124 to an incorrect identification of patient cultures. In the case presented here,
125 an automatic identification system misidentified the bacilli as
126 *Corynebacterium* spp.; however, actinomycosis was strongly suspected due to
127 the patient's background and clinical progression. Therefore, we performed
128 sequencing analysis of the 16S rRNA gene of the isolates and made a
129 confirmatory diagnosis using the biological characteristics of the cultured
130 bacteria. Culture contaminants are commonplace, and invasive *Nocardia*
131 infections are rare. Therefore, close collaboration between clinicians and
132 clinical laboratories is necessary for the optimal diagnosis and treatment of
133 patients.

134 Historically, sulphonamides have been the first-line therapy for the
135 treatment of nocardiosis, with TMP being the most commonly used
136 treatment. Sulpha drugs may reduce the mortality rate when used alone or

137 in combination with other antimicrobials [1,2]. In an immunocompromised
138 patient with severe, progressive infection or central nerve system
139 involvement, treatment should involve a combined therapy of either TMP
140 and a bactericidal agent or a combination of imipenem and amikacin [1-3].

141 In the current case, we decided to treat with amikacin (with close monitoring
142 of neurological status) and IPM despite the patient's diagnosis of MG, due to
143 the emergence of a drug allergy to TMP. Unfortunately, an allergic reaction
144 to IPM also occurred, and the renal abscess worsened; therefore, we
145 administered linezolid as a last line of defence.

146 Linezolid crosses the blood-brain barrier and has excellent bioavailability.
147 In vitro activity of linezolid against *Nocardia* spp. was observed in several
148 studies. Brown-Elliott et al. tested 140 clinical isolates by broth
149 microdilution and demonstrated that linezolid concentrations of 4 ug/mL
150 inhibited 90% isolates (90% minimum inhibitory concentration), which is in
151 susceptible range according to the proposed Clinical and Laboratory
152 Standard Institute MIC breakpoint. [4] In another study testing 93
153 *Nocardia* isolates by the Etest method, all isolates were susceptible to
154 linezolid. [5] Thus, it is an attractive alternative treatment for central

155 nervous system nocardiosis, despite limited clinical evidence to support this
156 claim.

157 Fifteen cases of nocardiosis treated with linezolid have been published to
158 date.(Table)[6-15] Linezolid has a well-documented short-term adverse
159 effect profile, with headache and diarrhoea most commonly seen; however,
160 its long-term safety profile (>28 days) has not been extensively studied. In
161 9 of these cases, linezolid was selected due to a lack of tolerance to TMP or
162 beta-lactams, and 2 cases were due to multidrug resistant *Nocardia* spp.
163 All cases exhibited long-term tolerance of linezolid (median 120; range
164 30-720 days) and 14 out of 15 cases showed either an improvement in or
165 complete clearance of the infection. Whether linezolid treatment is superior
166 to TMP or beta-lactam treatment is still unknown; however, this agent may
167 be a last resort for nocardiosis. Information on efficacy and outcomes
168 similar to this report will be important in treating *Nocardia* spp. infections,
169 due to the need for an extended course of treatment and the relative lack of
170 available data.

171 Although reviews of therapy for *Nocardia* infections recommend TMP as the
172 therapeutic drug of choice, sulphonamide-resistant *Nocardia* infections have

173 been reported in many countries, including the United States, Japan, France
174 and Britain[16,17]. TMP susceptibility varies geographically, and TMP
175 resistance ranges from a low of 32% for *N. brevicatena* to 93% for *N.*
176 *farcinica*. Multidrug resistance may also occur with *N. farcinica*, and thus
177 susceptibility varies among *Nocardia* species as well. In addition, Tremblay
178 et al. recently reported the high frequency of isolation of *N. farcinica* from
179 specimens that indicated invasive disease (such as brain or lung biopsies and
180 blood) [16]. Given the preponderance of invasive *N. farcinica* infection and
181 the frequent non- susceptibility of isolates to TMP, this drug may no longer
182 be the first choice in some regions.

183 Publication bias is an important consideration, as some authors hesitate to
184 publish or present cases with poor outcomes. Another limitation is that the
185 published evidence regarding the efficacy and safety of linezolid in patients
186 with nocardiosis is derived solely from a small subset of case reports.
187 Although the incidence of nocardiosis is thought to be on the rise, it remains
188 a rare opportunistic infection. Thus, it is difficult to establish the use of
189 linezolid in the therapeutic regimen for nocardiosis through randomised
190 controlled trials.

191 Additional accumulation of case reports regarding the use of linezolid in
192 Nocardia infections will be of use to clinicians and patients suffering from
193 disseminated nocardiosis.

194

195 Acknowledgement:

196 We would like to thank Professor Tohru Gonoï at Medical Mycology Research
197 Center, Chiba University for performing biological tests for Nocardia
198 indentification.

199

200 Funding: None

201 Ethical approval: Not required

202 Conflict of interest: No conflict of interest to declare

203

204

205

206

207

208

209

210

211

Reference

1. Sonnell TC, Mitchell DH, Iredell JR. *Nocardia* species. In: Mandell GL, Bebbett JE, Dolin R, eds. Principles and practice of infectious diseases. 7th ed. New York: Elsevier, 2010:3199-3207
2. Brown-Elliott BA, Brown JM, Conville PS, Wallace RJ Jr. Clinical and laboratory features of the *Nocardia* spp. based on current molecular taxonomy. Clin Microbiol Rev 2006; 19:259–82.
3. Ambrosioni J, Lew D, Ganbino J. Nocardiosis: updated clinical review and experience at a tertiary center. Infection 2010;38:89-97
4. Brown-Elliott BA, Ward SC, Crist CJ, Mann LB, Wilson RW, Wallace RJ Jr. In vitro activities of linezolid against multiple *Nocardia* species. Antimicrob Agents Chemother 2001;45:1295-7.
5. Glupczynski Y, Berhin C, Janssens M, Wauters G. Determination of antimicrobial susceptibility patterns of *Nocardia* spp. from clinical specimens by Etest. Clin Microbiol Infect 2006;12:905-12.
6. Lewis KE, Ebdon P, Wooster SL, Rees J, Harrison GA. Multi-system

- 234 infection with *Nocardia farcinica* therapy with linezolid and minocycline. J
235 Infect 2003; 46:199-202.
- 236
- 237 7. Moitra RK, Auckland C, Cawley M, Jones G, Cooper C. Systemic
238 nocardiosis in a splenectomized patient with systemic lupus erythematosus:
239 successful treatment using linezolid. J Clin Rheumatol 2003;9:47-50.
- 240
- 241 8. Moylett EH, Pacheco SE, Brown-Elliott BA, Perry TR, Buescher ES,
242 Birmingham MC et al. Clinical experience with linezolid for the treatment of
243 *Nocardia* infection. Clin Infect Dis 2003; 36: 313-8.
- 244
- 245 9. Rupprecht TA, Prister HW. Clinical experience with linezolid for the
246 treatment of central nervous system infections. Eur J Neurol
247 2005;12:536-42.
- 248
- 249 10. Vigano SM, Edefonti A, Ferraresso M, Ranzi ML, Grossi P, Righini A et al.
250 Successful medical treatment of multiple abscesses due to *Nocardia farcinica*
251 in pediatric renal transplant recipient. Pediatr Nephrol 2005;20:1186-8.
- 252
- 253 11. Justiniano M, Grlorioso S, Dold S, Espinoza LR. *Nocardia* brain
254 abscesses in a male patient with SLE: successful outcome despite delay in
255 diagnosis. Clin Rheumatol 2007;26:1020-2.
- 256

- 257 12. Rivero A, Garcia-Lazaro M, Perez-Camacho I, Natera C, del Carmen
258 Almodovar M et al. Successful long-term treatment with linezolid for
259 disseminated infection with multiresistant *Nocardia farcinica*. *Infection*
260 2008;36: 389-91.
261
- 262 13. Falcone M, Pompeo ME, Fabi F, Venditti M. Linezolid therapy for the
263 treatment of nocardia infection: report of a case and review of the literature.
264 *Le infezioni in Medicina* 2008;2:94-98
265
- 266 14. Al-Tawfiq JA, Al-Khatti AA. Disseminated systemic *Nocardia farcinica*
267 infection complicating alefacept and infliximab therapy in a patient with
268 severe psoriasis. *Int J Infect Dis.* 2010 Feb;14(2):e153-7
269
- 270 15. Shen Q, Zhou H, Li H, Zhou J. Linezolid combined with
271 trimethoprim-sulfamethoxazole therapy for the treatment of disseminated
272 nocardiosis. *J Med Microbiol.* 2011 ;7 :1043-5.
273
- 274 16. Tremblay J, Thibert L, Alarie I, Valiquette L, Pe'pin J. Nocardiosis in
275 Quebec, Canada, 1988– 2008. *Clin Microbiol Infect* 2010. July 15 epub
276
- 277 17. Uhde KB, Pathak S, McCullum I Jr., Jannat-Khah DP, Shadomy SV,
278 Dykewicz CA et al. Antimicrobial-resistant *Nocardia* isolates, United States,
279 1995–2004. *Clin Infect Dis* 2010;51:1445–8

Table Summary of cases of linezolid use for nocardiosis

No.	Age (y), Sex	Co-morbidities	Infection Site	Nocardia spp.	Indication	Outcome	Linezolid ADRs	Duration of Linezolid use (days)	Reference
1	NA/M	Trauma	Disseminated	<i>N. farcinica</i>	ADRs	Cure (followed by minocycline)	Myelosuppression, optic neuritis	150	[6]
2	29/F	SLE	Disseminated	<i>N. asteroides</i>	ADRs	Cure (followed by IPM and AMK)	Peripheral neuropathy	120	[7]
3	45/M	Silicosis/steroid	Disseminated	<i>N. asteroides</i>	ADRs	Cure	None	365	[8]
4	63/M	Silicosis/steroid	Disseminated	NA	Sulphona- mide allergy	Cure	Anemia	90	
5	54/F	None	Facial cellulitis	NA	Clinical failure	Cure (followed by TMP)	Anemia	60	

6	52/F	None	Disseminated	<i>N. otitidisca-</i> <i>varium</i>	ADRs	Cure	Anemia, thrombocytopenia, lactic acidosis, peripheral neuropathy	120	
7	6/M	CGD	Lung	<i>N. asteroides</i>	Clinical failure	Cure	None	790	
8	9/M	CGD	Disseminated	NA	ADRs	Cure	None	365	
9	58/M	NA/steroid	Brain abscesses	<i>N. farcinica</i>	NA	Improvement (followed by meropenem and amoxicillin/clav ulanate)	None	49	[9]
10	12/M	Kidney transplant	Brain abscesses	<i>N. farcinica</i>	Clinical failure	Cure	Anemia	60	[10]
11	37/M	SLE	Brain abscesses	<i>N. asteroides</i>	Adjunctive therapy	Improvement	NA	NA	[11]
12	42/F	Heart transplant	Brain abscesses	<i>N. farcinica</i>	Multidrug resistance	Cure	Mild sensory neuropathy	510	[12]

13	51/M	Churg-Strauss syndrome	Lung	<i>N. asteroides</i>	ADRs	Improvement	None	36	[13]
14	66/F	Psoriasis	Disseminated	<i>N. farcinica</i>	Multidrug resistance	Unchanged	None	NA	[14]
15	45/M	Renal transplant	Lung, Subcutaneous abscess	<i>N. asteroides</i>	Clinical failure	Cure	Anemia, thrombocytopenia	NA	[15]
16	59/F	MG	Disseminated	<i>N. farcinica</i>	ADRs	Cure (followed by TMP)	Mild thrombocytopenia	30	Present case

NA = not available; ADR = adverse drug reaction; SLE = systemic lupus erythematoses; CGD = chronic granulomatous disease; MG = myasthenia gravis